J. Rothenstein

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters, Scott Gettinger, Melissa L. Johnson et al. · Journal of Clinical Oncology · 2017 · 415 citations · Full text

Cloning of Transforming Growth Factor-β1 (TGF-β1) and Its Type II Receptor from Zebrafish Ovary and Role of TGF-β1 in Oocyte Maturation

Gurneet Kohli, Siqin Hu, Eric Clelland et al. · Endocrinology · 2003 · 95 citations · Full text

Human Growth, Zebrafish Ovary, Oocyte Maturation +19

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer

Martin Reck, Thomas Wehler, Francesco Orlandi et al. · Journal of Clinical Oncology · 2020 · 88 citations · Full text

Managing Treatment–Related Adverse Events Associated with Alk Inhibitors

J. Rothenstein, Nathalie Letarte · Current Oncology · 2014 · 67 citations · Full text

Adverse Events, Alk Inhibitors, Oncology +14

Company Stock Prices Before and After Public Announcements Related to Oncology Drugs

J. Rothenstein, George Tomlinson, Ian F. Tannock et al. · JNCI Journal of the National Cancer Institute · 2011 · 61 citations